Did our lack of domestic manufacturing capacity for a virus-based platform vaccine lead to a higher premium with the AstraZeneca vaccine?
On April 16th, 2021. See this statement in context.
On April 16th, 2021. See this statement in context.
April 16th, 2021 / 3:50 p.m.
Conservative
Michelle Rempel Conservative Calgary Nose Hill, AB
Did our lack of domestic manufacturing capacity for a virus-based platform vaccine lead to a higher premium with the AstraZeneca vaccine?
See context to find out what was said next.